DK0649659T3 - Rapamycinpræparat til intravenøs injektion - Google Patents

Rapamycinpræparat til intravenøs injektion

Info

Publication number
DK0649659T3
DK0649659T3 DK94307116T DK94307116T DK0649659T3 DK 0649659 T3 DK0649659 T3 DK 0649659T3 DK 94307116 T DK94307116 T DK 94307116T DK 94307116 T DK94307116 T DK 94307116T DK 0649659 T3 DK0649659 T3 DK 0649659T3
Authority
DK
Denmark
Prior art keywords
rapamycin
solution
intravenous injection
weight percent
rapamycin preparation
Prior art date
Application number
DK94307116T
Other languages
Danish (da)
English (en)
Inventor
Robert Paul Waranis
Thomas Waymond Leonard
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0649659T3 publication Critical patent/DK0649659T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94307116T 1993-09-30 1994-09-29 Rapamycinpræparat til intravenøs injektion DK0649659T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12952593A 1993-09-30 1993-09-30

Publications (1)

Publication Number Publication Date
DK0649659T3 true DK0649659T3 (da) 1999-06-23

Family

ID=22440422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94307116T DK0649659T3 (da) 1993-09-30 1994-09-29 Rapamycinpræparat til intravenøs injektion

Country Status (18)

Country Link
US (1) US5516770A (zh)
EP (1) EP0649659B1 (zh)
JP (1) JPH07149624A (zh)
KR (1) KR100452003B1 (zh)
CN (1) CN1112924C (zh)
AT (1) ATE172119T1 (zh)
AU (1) AU689792B2 (zh)
BR (1) BR9403949A (zh)
CA (1) CA2133179A1 (zh)
DE (1) DE69413921T2 (zh)
DK (1) DK0649659T3 (zh)
ES (1) ES2123101T3 (zh)
FI (1) FI944536A (zh)
HK (1) HK1012231A1 (zh)
HU (1) HU219477B (zh)
IL (1) IL111095A (zh)
SG (1) SG47562A1 (zh)
TW (1) TW461816B (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
WO1999063968A1 (fr) * 1998-06-10 1999-12-16 Wakamoto Pharmaceutical Co., Ltd. Preparations aqueuses contenant des medicaments faiblement solubles
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
EP1210350B1 (en) * 1999-08-18 2004-07-14 Wyeth Water soluble sdz-rad esters
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DE60136200D1 (de) 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
CA2493878C (en) * 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
CA2498191C (en) * 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8637070B2 (en) * 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US7241771B2 (en) 2005-03-07 2007-07-10 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
EP1865770A4 (en) * 2005-04-07 2010-12-29 Nitromed Inc EVALUATION OF THE GENETIC RISK OF CARDIAC INSUFFICIENCY: IMPACT OF THE GENETIC VARIATION OF NOS3
WO2007041680A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
EP1942909A4 (en) * 2005-10-04 2010-01-06 Nitromed Inc METHODS OF TREATING RESPIRATORY DISORDERS
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP1984010A4 (en) * 2006-02-17 2010-09-08 Nitromed Inc METHOD FOR USE OF HYDRALAZIN COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20090306027A1 (en) * 2006-04-10 2009-12-10 Nitomed, Inc. Genetic risk assessment in heart failure: impact of the genetic variation of g-protein beta 3 subunit polymorphism
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
US9101541B2 (en) 2010-04-28 2015-08-11 Cadila Healthcare Limited Stable solid pharmaceutical matrix compositions of sirolimus
CN111712231A (zh) 2018-02-23 2020-09-25 百多力股份公司 用于40-o-环状烃酯和相关结构的肠胃外制剂材料和方法
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
CN114366715A (zh) * 2022-01-28 2022-04-19 严鹏科 雷帕霉素自微乳注射剂及其制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
EP0042816B1 (de) * 1980-06-19 1984-04-18 Ciba-Geigy Ag Verfahren zur Herstellung von Pigmentlegierungen
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation

Also Published As

Publication number Publication date
US5516770A (en) 1996-05-14
HUT71100A (en) 1995-11-28
TW461816B (en) 2001-11-01
HU219477B (hu) 2001-04-28
KR950007858A (ko) 1995-04-15
SG47562A1 (en) 1998-04-17
EP0649659A1 (en) 1995-04-26
CN1109747A (zh) 1995-10-11
CN1112924C (zh) 2003-07-02
IL111095A (en) 1998-10-30
ATE172119T1 (de) 1998-10-15
FI944536A0 (fi) 1994-09-29
FI944536A (fi) 1995-03-31
IL111095A0 (en) 1994-11-28
DE69413921T2 (de) 1999-05-12
JPH07149624A (ja) 1995-06-13
HK1012231A1 (en) 1999-07-30
CA2133179A1 (en) 1995-03-31
EP0649659B1 (en) 1998-10-14
ES2123101T3 (es) 1999-01-01
DE69413921D1 (de) 1998-11-19
HU9402809D0 (en) 1995-01-30
AU7435194A (en) 1995-04-13
BR9403949A (pt) 1995-06-13
KR100452003B1 (ko) 2005-08-01
AU689792B2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
DK0649659T3 (da) Rapamycinpræparat til intravenøs injektion
TW427903B (en) Rapamycin formulation for IV injection
DK0650729T3 (da) Rapamycin-præparater til intravenøs injektion
DK0471161T3 (da) Pumpespraypræparat indeholdende nitroglycerin i en hydrofil vandig sammensætning
DE3671168D1 (de) Pharmazeutische zubereitung.
ES2124414T3 (es) Solucion inyectable destinada a la administracion intramuscular y subcutanea en animales.
EP0705110A4 (en) PERFUSION OF IMMUNOGLOBULINS IN HETEROGRAFTS
ES2044091T3 (es) Formulaciones anti-neoplasticas.